A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1)
Our research enhances the safety and tolerability profile of ESL, but the clinical use of ESL should be noticed and avoided in relation to AEs since it raises the risk of dermatitis exfoliative, stevens-johnson syndrome. Particular attention should be paid to DRESS in children and hyponatremia in the elderly.
Authors
- Ge Song (ORCID: https://orcid.org/0009-0000-4535-2112)
- Xian Zhang (ORCID: https://orcid.org/0000-0002-6055-0130)
- Chunliang Chen (ORCID: https://orcid.org/0000-0002-7511-1501)
- Rui Ma (ORCID: https://orcid.org/0000-0002-4725-8186)
- Jinjing Zhao
- Jing Xu
- Huafei Tang
- Qiang Zhao
Institutions
- Army Medical University (CN)
- Daping Hospital (CN)
- PLA 306 Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.3389/fphar.2024.1463560
- Citations
- 3
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.16